Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.

Padilha SCOS, Virtuoso S, Tonin FS, Borba HHL, Pontarolo R.

Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1335-1345. doi: 10.1007/s00787-018-1125-0. Epub 2018 Feb 19. Review.

PMID:
29460165
2.

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.

Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M.

Neuropsychiatr Dis Treat. 2017 Dec 29;14:103-115. doi: 10.2147/NDT.S146840. eCollection 2018. Review.

3.

Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Nery ESM, Bangs M, Liu P, Ahl J, Perahia D.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):700-707. doi: 10.1089/cap.2016.0110. Epub 2017 Apr 12.

PMID:
28402139
4.

Mechanistic Studies of the N-formylation of Edivoxetine, a Secondary Amine-Containing Drug, in a Solid Oral Dosage Form.

Hoaglund Hyzer CS, Williamson ML, Jansen PJ, Kopach ME, Scherer RB, Baertschi SW.

J Pharm Sci. 2017 May;106(5):1218-1238. doi: 10.1016/j.xphs.2017.01.026. Epub 2017 Feb 1.

PMID:
28159638
5.

Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?

Stauffer VL, Liu P, Goldberger C, Marangell LB, Nelson C, Gorwood P, Fava M.

J Clin Psychiatry. 2017 Mar;78(3):317-323. doi: 10.4088/JCP.15m09972.

PMID:
27685842
6.

Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

Ball SG, Ferguson MB, Martinez JM, Pangallo BA, Nery ES, Dellva MA, Sparks J, Zhang Q, Liu P, Bangs M, Goldberger C.

J Clin Psychiatry. 2016 May;77(5):635-42. doi: 10.4088/JCP.14m09619.

PMID:
27035159
7.

Leveraging BCS in Development: A Case Study.

Hoaglund Hyzer CS, Fadda HM, Rodriguez JO, Aburub A.

Mol Pharm. 2015 Oct 5;12(10):3685-90. doi: 10.1021/acs.molpharmaceut.5b00450. Epub 2015 Sep 17.

PMID:
26365521
8.

Fragment Couplings via CO2 Extrusion-Recombination: Expansion of a Classic Bond-Forming Strategy via Metallaphotoredox.

Le CC, MacMillan DW.

J Am Chem Soc. 2015 Sep 23;137(37):11938-41. doi: 10.1021/jacs.5b08304. Epub 2015 Sep 15.

10.

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.

Martinez JM, Ferguson MB, Pangallo BA, Oakes TM, Sparks J, Dellva MA, Zhang Q, Liu P, Bangs M, Ahl J, Goldberger C.

Drugs Context. 2015 May 13;4:212279. doi: 10.7573/dic.212279. eCollection 2015.

11.

Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.

Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, Ahl J, Perahia DG.

Curr Med Res Opin. 2015 Jun;31(6):1179-89. doi: 10.1185/03007995.2015.1037732. Epub 2015 May 6.

PMID:
25894953
12.

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Ball SG, Atkinson S, Sparks J, Bangs M, Goldberger C, Dubé S.

J Clin Psychopharmacol. 2015 Jun;35(3):266-72. doi: 10.1097/JCP.0000000000000302.

PMID:
25815754
13.

A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition.

Kielbasa W, Pan A, Pereira A.

Eur Neuropsychopharmacol. 2015 Mar;25(3):377-85. doi: 10.1016/j.euroneuro.2014.12.009. Epub 2015 Jan 5.

PMID:
25637266
14.

Criticisms of drugs in early development for the treatment of depression: what can be improved?

Wang SM, Han C, Pae CU.

Expert Opin Investig Drugs. 2015 Apr;24(4):445-53. doi: 10.1517/13543784.2014.985784. Epub 2014 Dec 20.

PMID:
25529224
15.

A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder.

Markowitz JS, Brinda BJ.

Expert Opin Drug Metab Toxicol. 2014 Sep;10(9):1289-99. doi: 10.1517/17425255.2014.939955. Epub 2014 Jul 14. Review.

PMID:
25019201
16.

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C.

J Affect Disord. 2014;167:215-23. doi: 10.1016/j.jad.2014.06.006. Epub 2014 Jun 14.

PMID:
24995890
17.

A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.

Lin DY, Kratochvil CJ, Xu W, Jin L, D'Souza DN, Kielbasa W, Allen AJ.

J Child Adolesc Psychopharmacol. 2014 May;24(4):190-200. doi: 10.1089/cap.2013.0043.

18.

Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers.

Gibbs AA, Bautista CE, Mowlem FD, Naudts KH, Duka DT.

J Psychiatry Neurosci. 2014 May;39(3):E24-31.

19.

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.

Kielbasa W, Tesfaye E, Luffer-Atlas D, Mitchell MI, Turik MA.

Eur J Clin Pharmacol. 2013 Dec;69(12):2011-9. doi: 10.1007/s00228-013-1572-y. Epub 2013 Aug 17.

20.

Telescoped approach to aryl hydroxymethylation in the synthesis of a key pharmaceutical intermediate.

Slattery CN, Deasy RE, Maguire AR, Kopach ME, Singh UK, Argentine MD, Trankle WG, Scherer RB, Moynihan H.

J Org Chem. 2013 Jun 21;78(12):5955-63. doi: 10.1021/jo400647t. Epub 2013 Jun 6.

PMID:
23718859

Supplemental Content

Loading ...
Support Center